Sugi Predict

Sugi Predict / Compounds / SCHEMBL91465

SCHEMBL91465

SCHEMBL91465

COc1nc(C)c(C)nc1N

nearest known ligand 0.48

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ CCNA2 P20248 1/20 0.38
▸ CDK2 P24941 1/20 0.38
▸ CCNA1 P78396 1/20 0.38
▸ LMNA P02545 2/20 0.37
▸ ALDH1A1 P00352 3/20 0.35
▸ KDM4E B2RXH2 2/20 0.35
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ PIK3CA P42336 1/20 0.31
▸ HPGD P15428 2/20 0.31
▸ GAA P10253 2/20 0.31
▸ IDO1 P14902 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL66555 0.81 LMNA (0.41) CCNA2CDK2CCNA1LMNAALDH1A1
SCHEMBL30505748 0.80 KMT2A (0.39) CCNA2CDK2CCNA1LMNAALDH1A1
SCHEMBL29131660 0.80 KMT2A (0.39) CCNA2CDK2CCNA1LMNAALDH1A1
SCHEMBL27842770 0.79 CCNA2 (0.38) CCNA2CDK2CCNA1LMNAALDH1A1
SCHEMBL84918 0.78 CCNA2 (0.32) CCNA2CDK2CCNA1LMNA
SCHEMBL3435300 0.75 MEN1 (0.36) ALDH1A1MEN1KMT2AGAA
SCHEMBL11836648 0.73 LMNA (0.58) LMNAALDH1A1KDM4EHPGDGAA
SCHEMBL34472783 0.73 LMNA (0.58) LMNAALDH1A1KDM4EHPGDGAA
SCHEMBL1731482 0.72 CCNA2 (0.36) CCNA2CDK2CCNA1LMNAALDH1A1
SCHEMBL10919972 0.72 CCNA2 (0.36) CCNA2CDK2CCNA1LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8865732-B2 Heterocyclic compounds and uses thereof NOVARTIS AG (CH) 2014-10-21 — — US disclosed
US-20130210818-A1 Novel Heterocyclic Compounds and Uses Thereof NOVARTIS AG (CH) 2013-08-15 — — US disclosed
US-8129394-B2 Heteroaryl-substituted imidazole compounds and uses thereof NOVARTIS AG (CH) 2012-03-06 — — US disclosed
EP-1467976-B1 N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES ASTRAZENECA AB (SE) 2011-11-23 — — EP disclosed
WO-2011081310-A3 PEPTIDE MARKER FOR CANCER DIAGNOSIS, AND CANCER DIAGNOSIS METHOD USING SAME 한국기초과학지원연구원 (KR) 2011-10-27 — — WO disclosed
US-20100081670-A1 N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES BAXTER ANDREW 2010-04-01 — — US disclosed
US-7662825-B2 2,3-Dichloro-N-(3-methoxy-5-methyl-2-pyrazinyl)-benzenesulphonamide; inflammatory diseases, such as asthma ASTRAZENECA AB (SE) 2010-02-16 — — US disclosed
US-20100003246-A1 Novel heterocyclic compounds and uses therof NOVARTIS AG (CH) 2010-01-07 — — US disclosed
US-7410972-B2 Compounds ASTRAZENECA AB (SE) 2008-08-12 — — US disclosed
EP-1633729-B1 SULPHONAMIDE COMPOUNDS THAT MODULATE CHEMOKINE RECEPTOR ACTIVITY (CCR4) ASTRAZENECA AB (SE) 2008-07-30 — — EP disclosed
US-20060025423-A1 N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases ASTRAZENECA AB (SE) 2006-02-02 — — US disclosed
EP-1458715-B1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2005-12-07 — — EP disclosed
US-20050075346-A1 Novel compounds ASTRAZENECA AB (SE) 2005-04-07 — — US disclosed
EP-1467976-A1 N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES AstraZeneca AB (SE) 2004-10-20 — — EP disclosed
EP-1458715-A1 NOVEL COMPOUNDS AstraZeneca AB (SE) 2004-09-22 — — EP disclosed
US-6683184-B2 ANTITUMOR AGENTS SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2004-01-27 — — US disclosed
WO-2003059893-A1 N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES ASTRAZENECA AB (SE) 2003-07-24 — — WO disclosed
WO-2003051870-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2003-06-26 — — WO disclosed
US-20030092910-A1 Piperazine derivatives and process for the preparation thereof SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2003-05-15 — — US disclosed
CN-1296477-A Piperazine derivatives and process for the preparation thereof SAMJIN PHARM CO LTD (KR) 2001-05-23 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060025423-A1 N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases CCL11, CCL2, CCR2 CCNA2 2580/4885CDK2 1971/4885CCNA1 1564/4885
US-20030092910-A1 Piperazine derivatives and process for the preparation thereof CBR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS CCNA2 950/4885CDK2 1996/4885CCNA1 145/4885
US-20100081670-A1 N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES CCL11, CCL2, CCR2 CCNA2 2580/4885CDK2 1971/4885CCNA1 1564/4885
US-20050075346-A1 Novel compounds CCL11, CCL2, CCL5 CCNA2 3019/4885CDK2 2319/4885CCNA1 2063/4885
US-20100003246-A1 Novel heterocyclic compounds and uses therof BRAF, ARAF, KRAS CCNA2 385/4885CDK2 20/4885CCNA1 533/4885
US-20130210818-A1 Novel Heterocyclic Compounds and Uses Thereof BRAF, RAF1, HRAS CCNA2 429/4885CDK2 34/4885CCNA1 483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.